XML 13 R2.htm IDEA: XBRL DOCUMENT v3.25.0.1
Condensed Consolidated Balance Sheets - USD ($)
Dec. 31, 2024
Jun. 30, 2024
Current assets    
Cash and cash equivalents $ 2,242,209 $ 6,304,098
Accounts receivable, net 266,080 429,704
Inventories, net 701,280 777,537
Research and development tax incentive receivable 375,687 525,332
Deferred charges 127,586
Other current assets 348,684 497,572
Total current assets 4,061,526 8,534,243
Property and equipment, net 537,225 565,850
Operating lease right-of-use assets 182,637 306,744
Intangibles, net 3,902,587 4,372,026
Total assets 8,683,975 13,778,863
Current liabilities    
Accounts payable and accrued expenses 1,074,716 1,704,568
Current portion of operating lease liabilities 205,945 274,834
Current portion of deferred grant income 2,299,644 2,486,668
Current employee benefit liabilities 416,929 469,381
Current portion of notes payable 405,535 515,282
Total current liabilities 4,402,769 5,450,733
Employee benefit liabilities, less current portion 63,283 63,615
Operating lease liabilities, less current portion 14,535 81,324
Total liabilities 4,480,587 5,595,672
Commitments and contingencies (Note 9)
Shareholders’ equity    
Common stock, $0.01 par value, 100,000,000 shares authorized, 4,807,068 and 3,456,000 shares issued and outstanding at December 31, 2024 and June 30, 2024, respectively 48,068 34,557
Treasury stock, at cost, 116 shares as of December 31, 2024 and June 30, 2024, respectively (1) (1)
Additional paid-in capital 61,856,832 60,971,740
Accumulated deficit (56,899,435) (51,964,332)
Accumulated other comprehensive loss (639,424) (712,614)
Total consolidated Intelligent Bio Solutions Inc. equity 4,366,040 8,329,350
Non-controlling interest (162,652) (146,159)
Total shareholders’ equity 4,203,388 8,183,191
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 8,683,975 $ 13,778,863